Compare WETH & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | BCDA |
|---|---|---|
| Founded | 1992 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 14.5M |
| IPO Year | N/A | N/A |
| Metric | WETH | BCDA |
|---|---|---|
| Price | $1.53 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 78.1K | ★ 96.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.55 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $43,519,385.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.45 | ★ N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.76 | $1.00 |
| 52 Week High | $3.68 | $3.20 |
| Indicator | WETH | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 46.16 |
| Support Level | $1.32 | $1.16 |
| Resistance Level | $1.57 | $1.32 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 75.54 | 52.25 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).